These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 27286995)

  • 1. Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment.
    Bridoux F; Chen N; Moreau S; Arnulf B; Moumas E; Abraham J; Desport E; Jaccard A; Fermand JP
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):173-82. PubMed ID: 27286995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study.
    Berdeja J; Jagannath S; Zonder J; Badros A; Kaufman JL; Manges R; Gupta M; Tendolkar A; Lynch M; Bleickardt E; Paliwal P; Vij R
    Clin Lymphoma Myeloma Leuk; 2016 Mar; 16(3):129-38. PubMed ID: 26795075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function.
    Dimopoulos M; Alegre A; Stadtmauer EA; Goldschmidt H; Zonder JA; de Castro CM; Masliak Z; Reece D; Olesnyckyj M; Yu Z; Weber DM
    Cancer; 2010 Aug; 116(16):3807-14. PubMed ID: 20564094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment.
    Zhou DB; Yu L; Du X; Jin J; Cai Z; Chen F; Ke X; Li X; Wu D; Meng F; Ai H; Zhang J; DeMarco D; Chen N; Mei J; Wang J; Hou J
    Int J Hematol; 2015 Jun; 101(6):569-77. PubMed ID: 25753225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment.
    Dimopoulos MA; Christoulas D; Roussou M; Kastritis E; Migkou M; Gavriatopoulou M; Matsouka C; Mparmparoussi D; Psimenou E; Grapsa I; Efstathiou E; Terpos E
    Eur J Haematol; 2010 Jul; 85(1):1-5. PubMed ID: 20192988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal.
    Kleber M; Ihorst G; Udi J; Koch B; Wäsch R; Engelhardt M
    Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):38-48. PubMed ID: 22054851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment.
    Klein U; Neben K; Hielscher T; Heiss C; Ho AD; Goldschmidt H
    Ann Hematol; 2011 Apr; 90(4):429-39. PubMed ID: 20857112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma.
    Dimopoulos MA; Cheung MC; Roussel M; Liu T; Gamberi B; Kolb B; Derigs HG; Eom H; Belhadj K; Lenain P; Van der Jagt R; Rigaudeau S; Dib M; Hall R; Jardel H; Jaccard A; Tosikyan A; Karlin L; Bensinger W; Schots R; Leupin N; Chen G; Marek J; Ervin-Haynes A; Facon T
    Haematologica; 2016 Mar; 101(3):363-70. PubMed ID: 26659916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials.
    Siegel DS; Weisel KC; Dimopoulos MA; Baz R; Richardson P; Delforge M; Song KW; San Miguel JF; Moreau P; Goldschmidt H; Cavo M; Jagannath S; Yu X; Hong K; Sternas L; Zaki M; Palumbo A
    Leuk Lymphoma; 2016 Dec; 57(12):2833-2838. PubMed ID: 27267105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial.
    Dimopoulos M; Weisel K; van de Donk NWCJ; Ramasamy K; Gamberi B; Streetly M; Offidani M; Bridoux F; de la Rubia J; Mateos MV; Ardizzoia A; Kueenburg E; Collins S; Di Micco A; Rosettani B; Li Y; Bacon P; Sonneveld P
    J Clin Oncol; 2018 Jul; 36(20):2035-2043. PubMed ID: 29394124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An open-label, pharmacokinetic study of lenalidomide and dexamethasone therapy in previously untreated multiple myeloma (MM) patients with various degrees of renal impairment - validation of official dosing guidelines.
    Chen CI; Cao Y; Trudel S; Reece DE; Kukreti V; Tiedemann R; Prica A; Paul H; Le LW; Levina O; Kakar S; Lau A; Chen H; Chen E
    Leuk Lymphoma; 2020 Aug; 61(8):1860-1868. PubMed ID: 32476520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial.
    Hou J; Du X; Jin J; Cai Z; Chen F; Zhou DB; Yu L; Ke X; Li X; Wu D; Meng F; Ai H; Zhang J; Wortman-Vayn H; Chen N; Mei J; Wang J
    J Hematol Oncol; 2013 Jun; 6():41. PubMed ID: 23782711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study.
    Mikhael J; Manola J; Dueck AC; Hayman S; Oettel K; Kanate AS; Lonial S; Rajkumar SV
    Blood Cancer J; 2018 Aug; 8(9):86. PubMed ID: 30190454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 German centers.
    Oehrlein K; Langer C; Sturm I; Pönisch W; Hahn-Ast C; Kuhn S; Weisel KC
    Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):191-6. PubMed ID: 22341857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma.
    Weisel KC; Dimopoulos MA; Moreau P; Lacy MQ; Song KW; Delforge M; Karlin L; Goldschmidt H; Banos A; Oriol A; Alegre A; Chen C; Cavo M; Garderet L; Ivanova V; Martinez-Lopez J; Knop S; Yu X; Hong K; Sternas L; Jacques C; Zaki MH; San Miguel J
    Haematologica; 2016 Jul; 101(7):872-8. PubMed ID: 27081177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expert consensus for the diagnosis and treatment of patients with renal impairment of multiple myeloma].
    Renal Impairment of Multiple Myeloma Collaborative Study Group
    Zhonghua Nei Ke Za Zhi; 2017 Nov; 56(11):871-875. PubMed ID: 29136724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenalidomide is effective and safe for the treatment of patients with relapsed multiple myeloma and very severe renal impairment.
    João C; Freitas J; Gomes F; Geraldes C; Coelho I; Neves M; Lúcio P; Esteves S; Esteves GV
    Ann Hematol; 2016 May; 95(6):931-6. PubMed ID: 27068406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy.
    Niesvizky R; Naib T; Christos PJ; Jayabalan D; Furst JR; Jalbrzikowski J; Zafar F; Mark T; Lent R; Pearse RN; Ely S; Leonard JP; Mazumdar M; Chen-Kiang S; Coleman M
    Br J Haematol; 2007 Sep; 138(5):640-3. PubMed ID: 17686058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with lenalidomide and dexamethasone in patients with multiple myeloma and renal impairment.
    Dimopoulos MA; Terpos E; Goldschmidt H; Alegre A; Mark T; Niesvizky R
    Cancer Treat Rev; 2012 Dec; 38(8):1012-9. PubMed ID: 22609463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study.
    Quach H; Fernyhough L; Henderson R; Corbett G; Baker B; Browett P; Blacklock H; Forsyth C; Underhill C; Cannell P; Trotman J; Neylon A; Harrison S; Link E; Swern A; Cowan L; Dimopoulos MA; Miles Prince H
    Br J Haematol; 2017 May; 177(3):441-448. PubMed ID: 28197996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.